Similar articles for PMID: 33293446

Year	Number of Results
1924	1
1934	1
2015	2
2016	20
2017	18
2018	28
2019	23
2020	14
2021	3
2024	0

1

From Compassionate Use to Phase 3 Trial: The Impact of Germany's PSMA-617 Literature.

Hope TA. Hope TA. J Nucl Med. 2020 Dec;61(Suppl 2):255S-256S. doi: 10.2967/jnumed.120.252122. J Nucl Med. 2020. PMID: 33293446 Free article. No abstract available.

2

¹⁷⁷Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

Rahbar K, Ahmadzadehfar H, Boegemann M. Rahbar K, et al. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):513-514. doi: 10.1007/s00259-017-3892-0. Epub 2017 Nov 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 29164300 No abstract available.

3

[¹⁷⁷Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].

Boegemann M, Schrader AJ, Rahbar K. Boegemann M, et al. Urologe A. 2017 Nov;56(11):1440-1444. doi: 10.1007/s00120-017-0510-5. Urologe A. 2017. PMID: 28986618 Review. German.

4

[PSMA radioligand therapy in patients with advanced prostate cancer].

Bögemann M, Herrmann K, Radtke JP, Rahbar K. Bögemann M, et al. Urologe A. 2020 Jun;59(6):680-686. doi: 10.1007/s00120-020-01205-w. Urologe A. 2020. PMID: 32333064 Review. German.

5

[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].

Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lützen U, Prasad V, Heinzel A, Heuschkel M, Ruf J, Bartenstein P, Krause BJ. Fendler WP, et al. Nuklearmedizin. 2016 Jun 28;55(3):123-8. Nuklearmedizin. 2016. PMID: 27350005 German.

6

Formulation of clinical-scale ¹⁷⁷Lu-PSMA-617: From laboratory to clinics.

Das T, Guleria M, Banerjee S. Das T, et al. Nucl Med Biol. 2016 Dec;43(12):836. doi: 10.1016/j.nucmedbio.2016.08.002. Epub 2016 Aug 13. Nucl Med Biol. 2016. PMID: 27591896 No abstract available.

7

[PSMA-targeted radioligand therapy in prostate cancer].

Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M. Heck MM, et al. Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3. Urologe A. 2017. PMID: 27885457 Review. German.

8

Radioligand therapy with ¹⁷⁷Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use.

Ahmadzadehfar H, Essler M, Schäfers M, Rahbar K. Ahmadzadehfar H, et al. Nucl Med Biol. 2016 Dec;43(12):835. doi: 10.1016/j.nucmedbio.2016.08.003. Epub 2016 Aug 13. Nucl Med Biol. 2016. PMID: 27616702 No abstract available.

9

Re: [¹⁷⁷Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study.

De Man K, Ost P. De Man K, et al. Eur Urol. 2019 Mar;75(3):536-537. doi: 10.1016/j.eururo.2018.11.005. Epub 2018 Nov 15. Eur Urol. 2019. PMID: 30447887 No abstract available.

10

TheraP: a randomized phase 2 trial of ¹⁷⁷ Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M; ANZUP TheraP team; Davis ID. Hofman MS, et al. BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22. BJU Int. 2019. PMID: 31638341 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

87 results

Results by year